Home /Archive /2020 /2020 №8 /2020_8_3

Visn. Nac. Akad. Nauk Ukr. 2020.(8): 29-37
https://doi.org/10.15407/visn2020.08.029

Serhiy V. Komisarenko
Palladin Institute of Biochemistry of the National Academy of Sciences of Ukraine, Kyiv, Ukraine
ORCID: https://orcid.org/0000-0002-3244-3194

SCIENTIST’S PURSUIT FOR CORONAVIRUS SARS-COV-2, WHICH CAUSES COVID-19: SCIENTIFIC STRATEGIES AGAINST PANDEMIC

The article provides a broad and thorough analysis of the current situation regarding the COVID-19 pandemic. The origin and structure of SARS-CoV-2 virus, ways of infection, features of the disease, COVID-19 diagnosis, the use of pharmaceuticals for the disease treatment, the formation of immunity against SARS-CoV-2, vaccines and the effectiveness of anti-epidemic quarantine measures are examined. The use of mathematical modeling of the epidemic process and the prospects of quarantine ending are discussed.
Keywords: COVID-19 pandemic, SARS-CoV-2 coronavirus, ways of infection, COVID-19 diagnosis, anti-viral immunity, vaccines, models of the epidemic process.

Language of article: ukrainian

Full text (PDF)

REFERENCES

  1. Reimann H.A. Landmark article Dec 24, 1938: An acute infection of the respiratory tract with atypical pneumonia. A disease entity probably caused by a filtrable virus. JAMA. 1984. 251(7): 936–944. DOI: https://doi.org/10.1001/jama.251.7.936
  2. Severe acute respiratory syndrome. https://en.wikipedia.org/wiki/Severe_acute_respiratory_syndrome
  3. Middle East respiratory syndrome. https://en.wikipedia.org/wiki/Middle_East_respiratory_syndrome
  4. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6
  5. In Ukraine — the first case of coronavirus. Ukrayinska pravda. March 3, 2020 (in Ukrainian). https://www.pravda.com.ua/news/2020/03/3/7242332/
  6. Wee S.-L., McNeil D.G.Jr. China Identifies New Virus Causing Pneumonialike Illness. https://www.nytimes.com/2020/01/08/health/china-pneumonia-outbreak-virus.html
  7. Lu R., Zhao X., Li J. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020. 395(10224): 565–574. DOI: https://doi.org/10.1016/s0140-6736(20)30251-8
  8. Beaudette F.R., Hudson C.B. Cultivation of the virus of infectious bronchitis. J. Am. Vet. Med. Assoc. 1937. 90: 51–58.
  9. Tyrrell D.A., Bynoe M.l. Cultivation of a novel type of common-cold virus in organ cultures. Br. Med. J. 1965. 1(5448): 1467–1470. DOI: https://doi.org/10.1136/bmj.1.5448.1467
  10. Woo P.C., Lau S.K., Huang Y., Yuen K.Y. Coronavirus diversity, phylogeny and interspecies jumping. Exp. Biol. Med. (Maywood). 2009. 234(10): 1117–1127. DOI: https://doi.org/10.3181/0903-mr-94
  11. Derek Wong’s Virology. http://virology-online.com/viruses/CORZA4.htm
  12. Phylogeny of SARS-like betacoronaviruses including novel coronavirus SARS-CoV-2. https://nextstrain.org/groups/blab/sars-like-cov
  13. Davidson H. First Covid-19 case happened in November, China government records show — report. https://www.theguardian.com/world/2020/mar/13/first-covid-19-case-happened-in-november-china-government-records-show-report
  14. Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020. 395(10223): 497–506. DOI: https://doi.org/10.1016/S0140-6736(20)30183-5
  15. Osborne H. Coronavirus Outbreak May Have Started As Early As September, Scientists Say. https://www.newsweek.com/coronavirus-outbreak-september-not-wuhan-1498566
  16. Zhou P., Yang X.L., Wang X.G. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020. 579(7798): 270–273. DOI: https://doi.org/10.1038/s41586-020-2012-7
  17. Readfearn G. How did coronavirus start and where did it come from? Was it really Wuhan’s animal market? https://www.theguardian.com/world/2020/apr/28/how-did-the-coronavirus-start-where-did-it-come-from-how-did-it-spread-humans-was-it-really-bats-pangolins-wuhan-animal-market
  18. Liu P., Jiang J.Z., Wan X.F., Hua Y., Li L., Zhou J., Wang X., Hou F., Chen J., Zou J., Chen J. Are pangolins the intermediate host of the 2019 novel coronavirus (SARS-CoV-2)? PLoS Pathog. 2020. 16(5): e1008421. DOI: https://doi.org/10.1371/journal.ppat.1008421
  19. Andersen K.G., Rambaut A., Lipkin W.I., Holmes E.C., Garry R.F. The proximal origin of SARS-CoV-2. Nat. Med. 2020. 26(4): 450–452. DOI: https://doi.org/10.1038/s41591-020-0820-9
  20. Shinkman P.D. U.S. Spy Agencies Weigh In on Coronavirus Rumors. https://www.usnews.com/news/national-news/articles/2020-04-30/coronavirus-not-man-made-director-of-national-intelligence-says
  21. Sanger D.E. Pompeo Ties Coronavirus to China Lab, Despite Spy Agencies’ Uncertainty. https://www.nytimes.com/2020/05/03/us/politics/coronavirus-pompeo-wuhan-china-lab.html
  22. Pennisi E. How bats have outsmarted viruses — including coronaviruses — for 65 million years. Science. Jul. 22, 2020. DOI: https://doi.org/10.1126/science.abd9595
  23. Scudellari M. The sprint to solve coronavirus protein structures — and disarm them with drugs. Nature News. 15 May 2020. DOI: https://doi.org/10.1038/d41586-020-01444-z
  24. Zhang L., Lin D., Sun X. et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science. 2020. 368(6489): 409–412. DOI: https://doi.org/10.1126/science.abb3405
  25. Wu F., Zhao S., Yu B., Chen Y.M., Wang W., Song Z.G., Hu Y., Tao Z.W., Tian J.H., Pei Y.Y., Yuan M.L., Zhang Y.L., Dai F.H., Liu Y., Wang Q.M., Zheng J.J., Xu L., Holmes E.C., Zhang Y.Z. A new coronavirus associated with human respiratory disease in China. Nature. 2020. 579(7798): 265–269. DOI: https://doi.org/10.1038/s41586-020-2008-3
  26. Schmidt A., Wolff M.H., Weber O. Coronaviruses with special emphasis on first insights concerning SARS. Springer, 2005. 232 p. DOI: https://doi.org/10.1007/b137625
  27. Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.-L., Abiona O., Graham B.S., McLellan J.S. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020. 367(6483): 1260–1263. DOI: https://doi.org/10.1126/science.abb2507
  28. Zhang X., Li Sh., Niu Sh. ACE2 and COVID-19 and the Resulting ARDS. Postgrad. Med. J. 2020. 96(1137): 403–407. https://doi.org/10.1136/postgradmedj-2020-137935
  29. Watanabe Ya., Allen J.D., Wrapp D., McLellan J.S., Crispin M. Site-specific glycan analysis of the SARS-CoV-2 spike. Science. 2020. 369(6501): 330–333. DOI: https://doi.org/10.1126/science.abb9983
  30. Hoffman M. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020. DOI: https://doi.org/10.1016/j.cell.2020.02.052
  31. Sakai K., Ami Y., Tahara M. et al. The Host Protease TMPRSS2 Plays a Major Role in in Vivo Replication of Emerging H7N9 and Seasonal Influenza. Viruses J. Virol. 2014. 88(10): 5608–5616. DOI: https://doi.org/10.1128/JVI.03677-13
  32. Vankadari N., Wilce J.A. Emerging WuHan (COVID-19) Coronavirus: Glycan Shield and Structure Prediction of Spike Glycoprotein and Its Interaction With Human CD26. Emerg. Microbes Infect. 2020. 9(1): 601–604. DOI: https://doi.org/10.1080/22221751.2020.1739565
  33. Wang K., Chen W., Zhou Y.-S. et al. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. bioRxiv. DOI: https://doi.org/10.1101/2020.03.14.988345
  34. Castelvetri L.C., Ojha R., Pedro L.D. et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and provides a possible pathway into the central nervous system. BioRxiv preprint. DOI: https://doi.org/10.1101/2020.06.07.137802
  35. Jia Y., Shen G., Zhang Y., Huang K.-S., Ho H.-Y., Hor W.-S., Yang C.-H., Li C., Wang W.-L. Analysis of the mutation dynamics of SARS-CoV-2 reveals the spread history and emergence of RBD mutant with lower ACE2 binding affinity. BioRxiv. 2020. DOI: https://doi.org/10.1101/2020.04.09.034942
  36. Zhang L., Jackson C.B., Mou H., Ojha A., Rangarajan E.S., Izard T., Farzan M., Choe H. The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. BioRxiv. June 12, 2020. DOI: https://doi.org/10.1101/2020.06.12.148726
  37. Thao T.T.N., Labroussaa F., Ebert N. et al. Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform. Nature. 2020. DOI: https://doi.org/10.1038/s41586-020-2294-9
  38. Sun J., Zhuang Zh., Zheng J. et al. Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment. Cell. 2020. 182: 1–10. DOI: https://doi.org/10.1016/j.cell.2020.06.010
  39. Gaglia M., Lakdawala S. What we do and do not know about COVID-19’s infectious dose and viral load. https://theconversation.com/what-we-do-and-do-not-know-about-covid-19s-infectious-dose-and-viral-load-135991
  40. Wang W., Xu Y., Gao R., Lu R., Han K., Wu G., Tan W. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA. 2020. 323(18): 1843–1844. DOI: https://doi.org/10.1001/jama.2020.3786
  41. Meyerowitz E.A., Richterman A.G., Quick M.P.H. A Summary of the COVID-19 Literature So Far. Medscape. May 18, 2020. https://www.medscape.com/viewarticle/930588
  42. To K.K., Tsang O.T., Chik-Yan Y.C. et al. Consistent detection of 2019 novel coronavirus in saliva. Clinical Infectious Diseases. 2020. DOI: https://doi.org/10.1093/cid/ciaa149
  43. Sex and Coronavirus Disease 2019 (COVID-19). https://www1.nyc.gov/assets/doh/downloads/pdf/imm/covid-sex-guidance.pdf
  44. Mandavilli A. Infected but Feeling Fine: The Unwitting Coronavirus Spreaders. The New York Times. July 9, 2020. https://www.nytimes.com/2020/03/31/health/coronavirus-asymptomatic-transmission.html
  45. Petri W. Infected with the coronavirus but not showing symptoms? A physician answers 5 questions about asymptomatic COVID-19. The Conversation. https://theconversation.com/infected-with-the-coronavirus-but-not-showing-symptoms-a-physician-answers-5-questions-about-asymptomatic-covid-19-137029
  46. van Doremalen N., Bushmaker T., Morris D.H., Holbrook M.G., Gamble A., Williamson B.N., Tamin A., Harcourt J.L., Thornburg N.J., Gerber S.I., Lloyd-Smith J.O., de Wit E., Munster V.J. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N. Engl. J. Med. 2020. 382(16): 1564–1567. DOI: https://doi.org/10.1056/NEJMc2004973
  47. Sungnak W., Huang N., Becavin C., Berg M., Queen R., Litvinukova M., Talavera-Lopez C., Maatz H., Reichart D., Sampaziotis F., Worlock K.B., Yoshida M., Barnes J.L., Lung H.C.A. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat. Med. 2020. 26: 681–687. DOI: https://doi.org/10.1038/s41591-020-0868-6
  48. All Your Coronavirus Questions, Answered. Time. May 8, 2020. https://time.com/5820118/coronavirus-questions-answered/
  49. Lewis D. Is the coronavirus airborne? Experts can’t agree. Nature News. April 2, 2020. https://www.nature.com/articles/d41586-020-00974-w
  50. Harrison L. Speech May Spread More COVID-19 Than Feces. Medscape. 19 May 2020. https://www.medscape.com/viewarticle/930799
  51. Coronavirus: WHO rethinking how Covid-19 spreads in air. BBC News. 8 July 2020. https://www.bbc.com/news/world-53329946
  52. Rapid Expert Consultation on SARS-CoV-2 Survival in Relation to Temperature and Humidity and Potential for Seasonality for the COVID-19 Pandemic (April 7, 2020). https://www.nap.edu/read/25771/chapter/1
  53. Recommendation Regarding the Use of Cloth Face Coverings, Especially in Areas of Significant Community-Based Transmission. https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover.html
  54. Advice on the use of masks in the context of COVID-19. https://www.who.int/publications-detail/advice-on-the-use-of-masks-in-the-community-during-home-care-and-in-healthcare-settings-in-the-context-of-the-novel-coronavirus-(2019-ncov)-outbreak
  55. Estimating the number of infections and the impact of non-pharmaceutical interventions on COVID-19 in 11 European countries. https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2020-03-30-COVID19-Report-13.pdf
  56. Mizutani T. Signal transduction in SARS-CoV-infected cells. Ann. NY Acad. Sci. 2007. 1102: 86–95. DOI: https://doi.org/10.1196/annals.1408.006
  57. Zimmer C. DNA Inherited From Neanderthals May Increase Risk of Covid-19. The New York Times. July 4, 2020. https://www.nytimes.com/2020/07/04/health/coronavirus-neanderthals.html
  58. Osterweil N. Case Fatality Rate for COVID-19 Near 1.4%, Increases With Age. https://www.medscape.com/viewarticle/927870
  59. Rabin R.C. In Italy, Coronavirus Takes a Higher Toll on Men. https://www.nytimes.com/2020/03/20/health/coronavirus-italy-men-risk.html
  60. Wenham C., Smith J., Morgan R. COVID-19: the gendered impacts of the outbreak. Lancet. 2020. 395(10227): 846–848. DOI: https://doi.org/10.1016/S0140-6736(20)30526-2
  61. Coronavirus in NY: Cases, maps, charts and resources. https://www.syracuse.com/coronavirus-ny/
  62. Wadman M. Sex hormones signal why virus hits men harder. Science. 2020: 368(6495): 1038–1039. DOI: https://doi.org/10.1126/science.368.6495.1038
  63. Zaiets K., Padilla R. Coronavirus, diabetes, obesity and other underlying conditions: Which patients are most at risk? https://www.usatoday.com/in-depth/news/2020/04/15/coronavirus-risk-90-patients-had-underlying-conditions/2962721001/
  64. Mallapaty S. Mounting clues suggest the coronavirus might trigger diabetes. https://www.nature.com/articles/d41586-020-01891-8
  65. Tan T., Khoo B., Mills E.G. et al. Association Between High Serum Total Cortisol Concentrations and Mortality From COVID-19. Lancet Diabetes Endocrinol. 2020. 8(8): 659-660. DOI: https://doi.org/10.1016/S2213-8587(20)30216-3
  66. Balfour H. Blood test could identify those most at risk from COVID-19. Drug Target Review. 22 May 2020. https://www.drugtargetreview.com/news/61778/blood-test-could-identify-those-most-at-risk-from-covid-19/
  67. Yan L., Zhang H.-T., Goncalves J. et al. An interpretable mortality prediction model for COVID-19 patients. Nat. Mach. Intell. 2020. 2: 283–288. DOI: https://doi.org/10.1038/s42256-020-0180-7
  68. Yong Sh.J. Vitamin D as an Independent Risk Factor for COVID-19 Death. https://medium.com/microbial-instincts/lack-of-vitamin-d-as-an-independent-risk-factor-for-covid-19-death-82365d0520fa
  69. Fang L., Karakiulakis G., Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? The Lancet. 2020. 8(4): E21. DOI: https://doi.org/10.1016/s2213-2600(20)30116-8
  70. Sama I.E., Ravera A., Santema B.T. et al. Circulating Plasma Concentrations of Angiotensin-Converting Enzyme 2 in Men and Women With Heart Failure and Effects of Renin-Angiotensin-Aldosterone Inhibitors. Eur. Heart J. 2020. 41(19): 1810–1817. DOI: https://doi.org/10.1093/eurheartj/ehaa373
  71. Murray S. New Evidence Concerning Safety of ACE Inhibitors, ARBs in COVID-19. https://www.pharmacytimes.com/news/new-evidence-concerning-safety-of-ace-inhibitors-arbs-in-covid-19
  72. de Simone G. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers. Council on Hypertension of the European Society of Cardiology. 13 Mar 2020. https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang
  73. Radzikowska U., Ding M., Tan G. et al. Distribution of ACE2, CD147, CD26 and Other SARS-CoV-2 Associated Molecules in Tissues and Immune Cells in Health and in Asthma, COPD, Obesity, Hypertension, and COVID-19 Risk Factors. Allergy. 2020. DOI: https://doi.org/10.1111/all.14429
  74. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf
  75. Liu R., Wang Y., Li J., Han H., Xia Z., Liu F., Wu K., Yang L., Liu X., Zhu C. Decreased T cell populations contribute to the increased severity of COVID-19. Clin. Chim. Acta. 2020. DOI: https://doi.org/10.1016/j.cca.2020.05.019
  76. Ying T., Li W., Dimitrov D.S. Discovery of T-Cell Infection and Apoptosis by Middle East Respiratory Syndrome Coronavirus. J. Infect. Dis. 2016. 213(6): 877–879. DOI: https://doi.org/10.1093/infdis/jiv381
  77. Shoenfeld Y. Corona (COVID-19) time musings: Our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning. Autoimmun. Rev. 2020. 19(6): 102538. DOI: https://doi.org/10.1016/j.autrev.2020.102538
  78. Cascella M., Rajnik M., Cuomo A., Dulebohn S.C., Di Napoli R. Features, Evaluation and Treatment Coronavirus (COVID-19). (Treasure Island (FL): Stat Pearls Publishing, 2020).
  79. Long B., Brady W.J., Koyfman A., Gottlieb M. Cardiovascular complications in COVID-19. The American Journal of Emergency Medicine. 2020. DOI: https://doi.org/10.1016/j.ajem.2020.04.048
  80. Xu L., Liu J., Lu M., Yang D., Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver International. 2020. 40(5): 998–1004. DOI: https://doi.org/10.1111/liv.14435
  81. Riphagen S., Gomez X., Gonzalez-Martinez C., Wilkinson N., Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. The Lancet. 2020. DOI: https://doi.org/10.1016/s0140-6736(20)31094-1
  82. Kwon D. From Headaches to ‘COVID Toes,’ Coronavirus Symptoms Are a Bizarre Mix. Blood clots and inflammation may underlie many of these complications. https://www.scientificamerican.com/article/from-headaches-to-covid-toes-coronavirus-symptoms-are-a-bizarre-mix1/
  83. Carod-Artal F.J. Neurological complications of coronavirus and COVID-19. Revista de Neurologia. 2020. 70(9): 311–322. DOI: https://doi.org/10.33588/rn.7009.2020179
  84. Brooks M. COVID-19 Tied to Wide Range of Neuropsychiatric Complications. Medscape. June 29, 2020. https://www.medscape.com/viewarticle/933136
  85. Cormier Z. How Covid-19 can damage the brain. BBC News. 23 June 2020. https://www.bbc.com/future/article/20200622-the-long-term-effects-of-covid-19-infection
  86. Yasgur B.S. Three Stages to COVID-19 Brain Damage, New Review Suggests. Medscape. June 29, 2020. https://www.medscape.com/viewarticle/933131
  87. Negro F. Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis? Swiss Med. Weekly. 2020. 150: w20249. DOI: https://doi.org/10.4414/smw.2020.20249
  88. Coronavirus disease (COVID-19) technical guidance: Laboratory testing for 2019-nCoV in humans. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance
  89. Summary table of available protocols in this document. https://www.who.int/docs/default-source/coronaviruse/whoinhouseassays.pdf?sfvrsn=de3a76aa_2
  90. SARS-CoV-2 Diagnostic Pipeline. https://www.finddx.org/covid-19/pipeline/
  91. Coronavirus Testing Picks Up in the U.S. Following Slow Start. https://www.diagnosticsworldnews.com/news/2020/03/17/coronavirus-testing-picks-up-in-the-u.s.-following-slow-start
  92. Liuqian L., Shulun H., Wei H. 14% of Recovered Covid-19 Patients in Guangdong Tested Positive Again. https://www.caixinglobal.com/2020-02-26/14-of-recovered-covid-19-patients-in-guangdong-tested-positive-again-101520415.html
  93. Omer S.B., Malani P., Del Rio C. The COVID-19 Pandemic in the US: A Clinical Update. JAMA. 2020. DOI: https://doi.org/10.1001/jama.2020.5788
  94. Parry R.L. Coronavirus patients can't relapse, South Korean scientists believe. https://www.thetimes.co.uk/article/coronavirus-patients-cant-relapse-south-korean-scientists-believe-rkm8zm7d9
  95. Ukraine has developed test systems to detect antibodies to coronavirus. The Day. April, 13, 2020. (in Ukrainian). https://day.kyiv.ua/uk/news/130420-ukrayina-rozrobyla-test-systemy-dlya-vyznachennya-antytil-do-koronavirusu
  96. Sona Nanotech Inc. Buy. http://cdn.ceo.ca.s3-us-west-2.amazonaws.com/1f8c1h6-SONA.SNANF.Initiation.Maxim.040220.pdf
  97. Sheridan C. Fast, portable tests come online to curb coronavirus pandemic. https://www.nature.com/articles/d41587-020-00010-2  
  98. Fletcher E.R., Vijay S.L. New COVID-19 Rapid Diagnostic Approved On ‘GeneXpert’ TB Platform; Could Pave Way For More Testing In Low- & Middle-Income Countries. https://healthpolicy-watch.org/new-covid-19-rapid-test-approved-for-genexpert-tb-platform-could-pave-way-for-more-testing-in-low-middle-income-countries/
  99. Coronavirus (COVID-19) Update: FDA Authorizes First Antigen Test to Help in the Rapid Detection of the Virus that Causes COVID-19 in Patients. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-antigen-test-help-rapid-detection-virus-causes
  100. Sofia 2 SARS antigen FIA. https://www.quidel.com/immunoassays/rapid-sars-tests/sofia-2-sars-antigen-fia
  101. Medical Companies Win Approval for Rapid Coronavirus Tests. https://www.wsj.com/articles/medical-companies-win-approval-for-rapid-coronavirus-tests-11585586147
  102. Broughton J.P., Deng X., Yu G. et al. CRISPR-Cas12-based detection of SARS-CoV-2. Nat. Biotechnol. 2020. DOI: https://doi.org/10.1038/s41587-020-0513-4
  103. Sanders J.M., Monogue M.L., Jodlowski T.Z., Cutrell J.B. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19). JAMA. 2020. 323(18): 1824–1836. DOI: https://doi.org/10.1001/jama.2020.6019
  104. Kupferschmidt K., Cohen J. Race to find COVID-19 treatments accelerates. Science. 2020. 367(6485): 1412–1413. DOI: https://doi.org/10.1126/science.367.6485.1412
  105. Rodell C.B. An ACE therapy for COVID-19. https://stm.sciencemag.org/content/12/541/eabb5676
  106. Leslie M. Biologists invent a new way to fight viruses with llama blood and molecular superglue. https://www.sciencemag.org/news/2020/05/biologists-invent-new-way-fight-viruses-llama-blood-and-molecular-super-glue
  107. Mulligan M.J., Lyke K.E., Kitchin N. et al. Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report. MedRXiv. DOI: https://doi.org/10.1101/2020.06.30.20142570
  108. Ravichandran S., Coyle E.M., Klenow L. et al. Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits. Sci. Transl. Med. 2020. 12(550): eabc3539. DOI: https://doi.org/10.1126/scitranslmed.abc3539
  109. Wang C., Li W., Drabek D., Okba N.M.A., van Haperen R., Osterhaus A.D.M.E., van Kuppeveld F.J.M., Haagmans B.L., Grosveld F., Bosch B.J. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat. Commun. 2020. 11(1): 2251. DOI: https://doi.org/10.1038/s41467-020-16256-y
  110. Chi X., Yan R., Zhang J. et al. A Neutralizing Human Antibody Binds to the N-terminal Domain of the Spike Protein of SARS-CoV-2. Science. 369(6504): 650–655. DOI: https://doi.org/10.1126/science.abc6952  
  111. Kramer J. Coronavirus Antibody Therapies Raise Hopes — and Skepticism. Scientific American. May 29, 2020. https://www.scientificamerican.com/article/coronavirus-antibody-therapies-raise-hopes-and-skepticism1/
  112. Yuan M., Wu N.C., Zhu X., et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science. 2020. 368(6491): 630–633. DOI: https://doi.org/10.1126/science.abb7269
  113. Jee Ch. A trial is under way of the first new antibody medicine developed to treat COVID-19. https://www.technologyreview.com/2020/06/01/1002475/trial-new-antibody-medicine-developed-to-treat-covid-19/
  114. Robbiani D.F., Gaebler C., Muecksch F. et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020. DOI: https://doi.org/10.1038/s41586-020-2456-9
  115. Kupferschmidt K. Scientists put survivors’ blood plasma to the test. https://science.sciencemag.org/content/368/6494/922
  116. Etherington D. FDA now allows treatment of life-threatening COVID-19 cases using blood from patients who have recovered. https://techcrunch.com/2020/03/24/fda-now-allows-treatment-of-life-threatening-covid-19-cases-using-blood-from-patients-who-have-recovered/
  117. Demura M., Takada N. Blood plasma treatment for coronavirus set for Japan trial. https://asia.nikkei.com/Business/Health-Care/Blood-plasma-treatment-for-coronavirus-set-for-Japan-trial
  118. Gharbharan A., Jordans C.C.E., van Kessel C.G. et al. Convalescent Plasma for COVID-19. A randomized clinical trial. MedRXiv. 2020. DOI: https://doi.org/10.1101/2020.07.01.20139857
  119. Biopharma encourages citizens who have undergone COVID-19 to become plasma donors for the development of drugs against coronavirus infection. Interfax-Ukraine. May, 8, 2020 (in Ukrainian). https://ua.interfax.com.ua/news/general/661051.html
  120. Lovett S. Coronavirus: Men produce more COVID-19 antibodies than women, study shows. https://www.independent.co.uk/news/health/coronavirus-antibodies-men-women-blood-plasma-donor-a9579441.html
  121. The fight against COVID-19 starts with you. https://www.covig-19plasmaalliance.org/en-US#recruitment
  122. Al Idrus A. Takeda, CSL-led alliance and NIH to test COVID-19 plasma treatment this summer. https://www.fiercebiotech.com/biotech/takeda-csl-led-alliance-and-nih-to-test-plasma-treatment-summer
  123. Cohen E. Human Trials Expected To Start Next Month For Covid-19 Treatment Derived From Cows’ Blood. https://www.sabbiotherapeutics.com/2020/06/16/human-trials-expected-to-start-next-month-for-covid-19-treatment-derived-from-cows-blood/
  124. Sheridan C. Convalescent serum lines up as first-choice treatment for coronavirus. https://www.nature.com/articles/d41587-020-00011-1
  125. The first patient tests new drug against COVID-19. https://www.en.auh.dk/press-room/news-archive/2020/the-first-patient-tests-new-drug-against-covid-19/
  126. Camostat Mesylate in COVID-19 Outpatients. https://clinicaltrials.gov/ct2/show/NCT04353284
  127. Devaux C.A., Rolain J.M., Colson P., Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int. J. Antimicrob Agents. 2020. DOI: https://doi.org/10.1016/j.ijantimicag.2020.105938
  128. Piller C. Former FDA leaders decry emergency authorization of malaria drugs for coronavirus. https://www.sciencemag.org/news/2020/04/former-fda-leaders-decry-emergency-authorization-malaria-drugs-coronavirus
  129. Sciama Y. Is France’s president fueling the hype over an unproven coronavirus treatment? https://www.sciencemag.org/news/2020/04/france-s-president-fueling-hype-over-unproven-coronavirus-treatment
  130. Some Swedish hospitals have stopped using chloroquine to treat COVID-19 after reports of severe side effects. https://www.newsweek.com/swedish-hospitals-chloroquine-covid-19-side-effects-1496368
  131. FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems. https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or
  132. Remdesivir. https://en.wikipedia.org/wiki/Remdesivir#cite_note-:0-4
  133. Yin W., Mao C., Luan X. et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science. 2020. DOI: https://doi.org/10.1126/science.abc1560
  134. Gordon C.J., Tchesnokov E.P., Woolner E., Perry J.K., Feng J.Y., Porter D.P., Gotte M. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J. Biol. Chem. 2020. DOI: https://doi.org/10.1074/jbc.RA120.013679
  135. NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19. https://www.niaid.nih.gov/news-events/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19
  136. Grein J., Ohmagari N., Shin D. et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N. Engl. J. Med. 2020. DOI: https://doi.org/10.1056/NEJMoa2007016
  137. FDA Allows For 'Emergency Use' of Remdesivir, Experimental Coronavirus Drug. https://time.com/5831062/fda-allows-emergency-use-remdesivir/
  138. Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment
  139. Shimbun A. Japan approves remdesivir for COVID-19 despite uncertainties. http://www.asahi.com/ajw/articles/13358075
  140. Taylor Ph. Remdesivir closes in on receiving first EU approval for treatment for COVID-19. https://www.pmlive.com/pharma_news/remdesivir_closes_in_on_receiving_first_eu_approval_for_treatment_for_covid-19_1343030
  141. Ridgeback Biotherapeutics Announces Launch of Phase 2 Trials Testing EIDD-2801 as Potential Treatment for COVID-19. https://www.businesswire.com/news/home/20200619005038/en/Ridgeback-Biotherapeutics-Announces-Launch-Phase-2-Trials
  142. Lopinavir/ritonavir. https://en.wikipedia.org/wiki/Lopinavir/ritonavir
  143. Choy K.T., Wong A.Y., Kaewpreedee P. et al. Remdesivir, Lopinavir, Emetine, and Homoharringtonine Inhibit SARS-CoV-2 Replication in Vitro. Antiviral Res. 2020. 178: 104786. DOI: https://doi.org/10.1016/j.antiviral.2020.104786
  144. The WHO Solidarity Trial for COVID-19 treatments officially launched in Indonesia. https://www.who.int/indonesia/news/detail/24-04-2020-the-who-solidarity-trial-for-covid-19-treatments-officially-launched-in-indonesia
  145. Li Y., Xie Z., Lin W. et al. An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI). DOI: https://doi.org/10.1101/2020.03.19.20038984
  146. Hung I.F., Lung K.C., Tso E.Y. et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020. DOI: https://doi.org/10.1016/S0140-6736(20)31042-4
  147. WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19. https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19
  148. Kadhim A.A.H., Hadi N.R., Abdulhussein M., Zamil S.T., Zamil S.T. Preprocessing of the Candidate Antiviral Drugs against COVID-19 in Models of SARS cov2 Targets. LPMA. 2020. 106(2): 240.
  149. Rossignol J.F., Maisonneuve H. Nitazoxanide in the treatment of Taenia saginata and Hymenolepis nana infections. Am. J.Trop. Med. Hyg. 1984. 33: 511–512. DOI: https://doi.org/10.4269/ajtmh.1984.33.511
  150. Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z., Zhong W., Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020. 30(3): 269–271. DOI: https://doi.org/10.1038/s41422-020-0282-0
  151. Scientists Identify 69 Drugs to Test Against the Coronavirus. https://www.nytimes.com/2020/03/22/science/coronavirus-drugs-chloroquine.html
  152. Jin Z., Du X., Xu Y. et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020. DOI: https://doi.org/10.1038/s41586-020-2223-y
  153. The Coronavirus Patients Betrayed by Their Own Immune Systems. https://www.nytimes.com/2020/04/01/health/coronavirus-cytokine-storm-immune-system.html
  154. Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection. https://clinicaltrials.gov/ct2/show/NCT04324021
  155. Sagonowsky E. Roche's Actemra falls short in Italian study in early-stage COVID-19 pneumonia. https://www.fiercepharma.com/pharma/roche-s-actemra-fails-italian-study-early-stage-covid-19-pneumonia
  156. Horby P., Lim W.Sh., Emberson J. et al. RECOVERY Collaborative Group Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. MedRXiv. DOI: https://doi.org/10.1101/2020.06.22.20137273
  157. Poperechna D. MOZ vneslo novyy preparat u protokol likuvannya COVID-19. Ukrayinska pravda. June 25, 2020. https://life.pravda.com.ua/health/2020/06/25/241465/
  158. Yasgur B.S. Colchicine Promising in COVID-19 Treatment? https://www.medscape.com/viewarticle/933198
  159. Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. https://www.bmj.com/content/368/bmj.m1086
  160. Ioannou P. Rapid Response: Re: Non-steroidal anti-inflammatory drugs and COVID-19; An ambiguous correlation. https://www.bmj.com/content/368/bmj.m1185/rr-0
  161. Godoy M. Concerned About Taking Ibuprofen For Coronavirus Symptoms? Here's What Experts Say. https://www.npr.org/sections/health-shots/2020/03/18/818026613/advice-from-france-to-avoid-ibuprofen-for-covid-19-leaves-experts-baffled
  162. Klok F.A., Kruip M.J.H.A., van der Meer N.J.M., Arbous M.S., Gommers D.A.M.P.J., Kant K.M., Kaptein F.H.J., van Paassen J., Stals M.A.M., Huisman M.V., Endeman H. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis Research. 2020. DOI: https://doi.org/10.1016/j.thromres.2020.04.013
  163. Tang N., Bai H., Chen X., Gong J., Li D., Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of Thrombosis and Haemostasis. 2020. 18(5): 1094–1099. DOI: https://doi.org/10.1111/jth.14817
  164. Lugovskoy E.V., Kolesnikova I.N., Gritsenko P.G., Komissarenko S.V. Utilization of monoclonal antibodies for the quantification of molecular markers of hemostasis. Journal of Thrombosis and Haemostasis. 2003. 1(Suppl. 1): CD084. (XIX Congress of the International Society on Thrombosis and Haemostasis, Birmingham, UK, July 12-18, 2003.)
  165. Lugovskoy E.V., Gritsenko P.G., Kolesnikova I.N., Zolotareva E.N., Chernishov V.I., Nieuwenhuizen W., Komisarenko S.V. Two monoclonal antibodies to D-dimer-specific inhibitors of fibrin polymerization.Thrombosis Research. 2004. 113(3-4): 251–259. DOI: https://doi.org/10.1016/j.thromres.2004.03.005
  166. Collaboration initiated to develop COVID-19 immunotherapy. https://www.drugtargetreview.com/news/58326/collaboration-initiated-to-develop-covid-19-immunotherapy/
  167. Could T-cell immunotherapy be the answer to COVID-19? https://www.drugtargetreview.com/news/60482/could-t-cell-immunotherapy-be-the-answer-to-covid-19/
  168. Borrell B. New York clinical trial quietly tests heartburn remedy against coronavirus. Science. Apr. 26, 2020. DOI: https://doi.org/10.1126/science.abc4739
  169. Koch S., Pong W. First up for COVID-19: nearly 30 clinical readouts before end of April. https://www.biocentury.com/article/304658/nearly-30-trials-for-covid-19-could-start-to-yield-data-in-the-next-couple-of-months
  170. Lim G.Y. TCM and COVID-19: China conducting trials to test efficacy and safety of traditional herbal interventions. https://www.nutraingredients-asia.com/Article/2020/04/06/TCM-and-COVID-19-China-conducting-trials-to-test-efficacy-and-safety-of-traditional-herbal-interventions
  171. Chapin E. Artemisia Annua Could Be Promising Treatment for COVID-19. https://uknow.uky.edu/research/artemisia-annua-could-be-promising-treatment-covid-19
  172. Wadman M. Can interferons stop COVID-19 before it takes hold? Science. 2020: 369(6500): 125–126. DOI: https://doi.org/10.1126/science.369.6500.125
  173. Kupferschmidt K. These Drugs Don’t Target the Coronavirus – They Target Us. https://www.sciencemag.org/news/2020/04/these-drugs-don-t-target-coronavirus-they-target-us
  174. Lipsitch M. Who Is Immune to the Coronavirus? https://www.nytimes.com/2020/04/13/opinion/coronavirus-immunity.html
  175. COVID-19 Antibodies Can Disappear After 2-3 Months, Study Shows. https://www.medscape.com/viewarticle/932671
  176. To K.K.-W., Cheng V.Ch.-Ch., Cai J.-P. et al. Seroprevalence of SARS-CoV-2 in Hong Kong and in residents evacuated from Hubei province, China: a multicohort study. Lancet Microbe. 2020. DOI: https://doi.org/10.1016/S2666-5247(20)30053-7
  177. Dr. Fauci Explains The Timeline And Risks Of Creating A COVID-19 Vaccine. MSNBC. https://www.youtube.com/watch?v=ZrWAqpPGAxQ
  178. CEPI. https://cepi.net/covid-19/
  179. Berkley S. COVID-19 needs a big science approach. https://science.sciencemag.org/content/367/6485/1407
  180. Zheng M., Song L. Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV. Cell. Mol. Immunol. 2020. 17(5): 536–538. DOI: https://doi.org/10.1038/s41423-020-0385-z
  181. Achenbach J. The coronavirus isn’t mutating quickly, suggesting a vaccine would offer lasting protection. https://www.washingtonpost.com/health/the-coronavirus-isnt-mutating-quickly-suggesting-a-vaccine-would-offer-lasting-protection/2020/03/24/406522d6-6dfd-11ea-b148-e4ce3fbd85b5_story.html
  182. Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus. https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-interim-phase-1-data-its-mrna-vaccine
  183. Funk C.D., Laferriere C., Ardakani A. A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic. Front. Pharmacol. 2020. 11:937. DOI: https://doi.org/10.3389/fphar.2020.00937
  184. Cohen J. Vaccine designers take first shots at COVID-19. Science. 2020. 368(6486): 14–16. DOI: https://doi.org/10.1126/science.368.6486.14
  185. Callaway E. The race for coronavirus vaccines: a graphical guide. Nature. 2020. 580: 576-577. DOI: https://doi.org/10.1038/d41586-020-01221-y
  186. Gao Q., Bao L., Mao H. et al. Rapid development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020. 369(6499): eabc1932. DOI: https://doi.org/10.1126/science.abc1932
  187. Mueller S., Stauft C.B., Kalkeri R. et al. A codon-pair deoptimized live-attenuated vaccine against respiratory syncytial virus is immunogenic and efficacious in non-human primates. Vaccine. 2020. 38(14): 2943–2948. DOI: https://doi.org/10.1016/j.vaccine.2020.02.056
  188. Yu J., Tostanoski L.H., Peter L. et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020. 20 May 2020: eabc6284. DOI: https://doi.org/10.1126/science.abc6284
  189. Draft landscape of COVID-19 candidate vaccines. WHO. https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines
  190. Oxford COVID-19 vaccine to begin phase II/III human trials. http://www.ox.ac.uk/news/2020-05-22-oxford-covid-19-vaccine-begin-phase-iiiii-human-trials
  191. Lauerman J. Oxford, AstraZeneca Begin Advanced Trials of Covid Vaccine. Bloomberg. 22 May 2020. https://www.bloomberg.com/news/articles/2020-05-22/oxford-astrazeneca-begin-advanced-trials-of-covid-vaccine
  192. Folegatti P.M., Ewer K.J., Aley P.K., et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet. 20 July, 2020. DOI: https://doi.org/10.1016/S0140-6736(20)31604-4
  193. Zhu F.-C., Li Y.-H., Gua X.-H. et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020. 395: 1845–1854. DOI: https://doi.org/10.1016/S0140-6736(20)31208-3
  194. Haseltine W.A. Lessons for COVID-19 from the Early Days of AIDS. Scientific American. July 6, 2020.https://www.scientificamerican.com/article/lessons-for-covid-19-from-the-early-days-of-aids/
  195. Accelerating a safe and effective COVID-19 vaccine. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/accelerating-a-safe-and-effective-covid-19-vaccine
  196. Draft landscape of COVID-19 candidate vaccines. WHO. 21 July, 2020. https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines
  197. Ramesh S. Can BCG vaccine protect against Covid-19? Here’s why the excitement needs to be tempered. https://theprint.in/science/can-bcg-vaccine-protect-against-covid-19-heres-why-the-excitement-needs-to-be-tempered/401449/
  198. Sparber S. Texas A&M researchers hope tuberculosis vaccine might prevent coronavirus deaths. https://www.krgv.com/news/texas-aandm-researchers-hope-tuberculosis-vaccine-might-prevent-coronavirus-deaths/
  199. Brook B., Harbeson D.J., Shannon C.P. et al. BCG vaccination-induced emergency granulopoiesis provides rapid protection from neonatal sepsis. Sci. Transl. Med. 2020. 12(542): eaax4517. DOI: https://doi.org/10.1126/scitranslmed.aax4517
  200. Arts R.J.W., Moorlag S.J.C.F.M., Novakovic B., Li Y., Wang S.Y., Oosting M., Kumar V., Xavier R.J., Wijmenga C., Joosten L.A.B., Reusken C.B.E.M., Benn C.S., Aaby P., Koopmans M.P., Stunnenberg H.G., van Crevel R., Netea M.G. BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity. Cell Host Microbe. 2018. 23(1): 89–100.e5. DOI: https://doi.org/10.1016/j.chom.2017.12.010
  201. A $10M Grant Enables BCG Vaccine Trial to Expand Internationally, Enrol 10,000 Healthcare Workers. https://www.combacte.com/press-releases/11244/
  202. Chumakov K., Benn C.S., Aaby P., Kottilil Sh., Gallo R. Can existing live vaccines prevent COVID-19? Science. 2020. 368(6496): 1187–1188. DOI: https://doi.org/0.1126/science.abc4262
  203. Escobar L.E., Molina-Cruz A., Barillas-Mury C.BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). PNAS. 2020. 117(30): 17720–17726. DOI: https://doi.org/10.1073/pnas.2008410117
  204. Hamiel U., Kozer E., Youngster I. SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults. JAMA. 2020. 323(22): 2340–2341. DOI: https://doi.org/10.1001/jama.2020.8189
  205. Woodley M. Healthcare workers trial TB vaccine for coronavirus protection. newsGP. 27 Mar 2020. https://www1.racgp.org.au/newsgp/clinical/healthcare-workers-to-trial-tuberculosis-vaccine-f
  206. Kramer A.E. Decades-Old Soviet Studies Hint at Coronavirus Strategy. https://www.nytimes.com/2020/06/24/world/europe/vaccine-repurposing-polio-coronavirus.html
  207. Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/Imperial-College-COVID19-NPI-modelling-16-03-2020.pdf
  208. Yang Y.Q., Sun Q., Wang Y.X., et al. Epidemic situation analysis and trend forecast of New Coronavirus Pneumonia (NCP) in Chongqing (in Chinese). Journal of Chongqing Normal University (Natural Science). 2020. 37(1). DOI: https://doi.org/10.1101/2020.02.17.20024034
  209. Brovchenko I. Development of the mathematical model of Covid-19 epidemic spread in Ukraine. Svitohliad. 2020. 2(82): 2–14. (in Ukrainian). https://www.mao.kiev.ua/biblio/jscans/svitogliad/svit-2020-15-2/svitoglyad-2020-2-2-brovchenko.pdf
  210. National coronavirus response: A road map to reopening. https://www.aei.org/research-products/report/national-coronavirus-response-a-road-map-to-reopening/
  211. European countries are easing quarantine restrictions. http://lowcostavia.com.ua/europe-poslablyuye-karantynni-obmezhennya/
  212. Prime Minister Denys Shmyhal unveils a step-by-step quarantine exit plan. Government of Ukraine. Official website. April 24, 2020. https://www.kmu.gov.ua/en/news/premyer-ministr-denis-shmigal-predstaviv-poetapnij-plan-znyattya-obmezhen  
  213. Ukrayina perekhodyt do nastupnoho etapu poslablennya karantynu. Ukrayinska pravda. June 1, 2020. (in Ukrainian). https://www.pravda.com.ua/news/2020/06/1/7253960/
  214. Leshner A. Restart science stronger after COVID-19. Science. 2020. 369(6502): 262. DOI: https://doi.org/10.1126 / science.abd5780